Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,205 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,005 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02155088 | BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer | completed | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT02985801 | PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 16 | Massimo Raimondo, M.D.OTHER | 1 | Mar 15, 2021 |
| clinicaltrials |
| NCT02154737 | Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer | completed | Phase 1 | 24 | Tony Reid, M.D., Ph.D.OTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT04764084 | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors | unknown | Phase 1 | 52 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT03703063 | Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer | unknown | Phase 1 | 30 | Benaroya Research InstituteOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | completed | Phase 1 | 47 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT03760614 | A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jan 15, 2021 | clinicaltrials |
| NCT04707118 | Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy | unknown | Phase 1 | 106 | Fudan UniversityOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04425876 | A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer | unknown | Phase 1 | 74 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 31, 2020 | clinicaltrials |
| NCT03207724 | Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia(OnFX) | completed | Phase 1 | 16 | Andrew Hendifar, MDOTHER | 1 | Dec 30, 2020 | clinicaltrials |
| NCT03989310 | An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT00560963 | Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine | completed | Phase 1 / Phase 2 | 21 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01487785 | Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 19, 2020 | clinicaltrials |
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03438435 | Fluorescence QRH-882260 Peptide Imaging in the Bile Duct | completed | Phase 1 | 1 | D. Kim Turgeon, MDOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT03291938 | IACS-010759 in Advanced Cancers | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03790423 | 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer | completed | Phase 1 | 10 | Rigshospitalet, DenmarkOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT01828034 | First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma | completed | Phase 1 / Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT03180437 | Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 62 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | terminated | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02045602 | Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | Theriva Biologics SLINDUSTRY | 1 | Oct 8, 2020 | clinicaltrials |
| NCT02101580 | Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer | completed | Phase 1 | 21 | Polaris GroupINDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT01385956 | SOM 230 and Gemcitabine in Advanced Pancreatic Cancer | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT02355535 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | completed | Phase 1 | 48 | Vanquish Oncology, Inc.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01938729 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma | completed | Phase 1 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT01189929 | A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 1 | 57 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 9, 2020 | clinicaltrials |
| NCT02005315 | A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer | completed | Phase 1 | 30 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02050178 | Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer | completed | Phase 1 | 26 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT00769483 | MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT01485744 | LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer | completed | Phase 1 | 39 | Massachusetts General HospitalOTHER | 1 | Aug 4, 2020 | clinicaltrials |
| NCT03943043 | Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 85 | Istituto Clinico HumanitasOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT02092948 | Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer | completed | Phase 1 | 8 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT03507998 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | unknown | Phase 1 | 39 | Curegenix Inc.INDUSTRY | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03734926 | A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 90 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT04482257 | Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. | unknown | Phase 1 | 48 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT01908478 | Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer(VelGemRad) | completed | Phase 1 | 34 | Cedars-Sinai Medical CenterOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT00576680 | RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 1 / Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT03415126 | A Study of ASN007 in Patients With Advanced Solid Tumors | completed | Phase 1 | 49 | Asana BioSciencesINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT03168139 | Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer(Keynote-559) | completed | Phase 1 / Phase 2 | 20 | TME Pharma AGINDUSTRY | 1 | Jul 8, 2020 | clinicaltrials |
| NCT01092689 | The Role of Meat-borne Carcinogens in Pancreatic Cancer | withdrawn | Phase 1 | 0 | University of MinnesotaOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT02599662 | Intraoperative Radiation Therapy for Resectable Pancreas Cancer(IORT) | unknown | Phase 1 | 12 | Loyola UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT01803282 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | completed | Phase 1 | 236 | Gilead SciencesINDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT00255827 | Vaccine Treatment for Surgically Resected Pancreatic Cancer | completed | Phase 1 / Phase 2 | 7 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors(D-1MT) | terminated | Phase 1 | 17 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03027284 | A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer | completed | Phase 1 | 19 | Eli Lilly and CompanyINDUSTRY | 1 | May 19, 2020 | clinicaltrials |
| NCT02261714 | Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer | completed | Phase 1 / Phase 2 | 32 | Targovax ASAINDUSTRY | 3 | May 14, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Apr 8, 2021source: clinicaltrials